Under the agreement, Lupin’s Philippines subsidiary, Multicare Pharmaceuticals, and its Brazil subsidiary, MedQuimica, will market and promote Plasil, which contains metoclopramide. Shares of Lupin Ltd ended at ₹2,116.00, down by ₹2.90, or 0.14%, on the BSE.
